Relationship and Clinical Significance of ALDH1A1 and CD133 Cancer Stem Cell Markers and Mutant p53 in Lung Adenocarcinoma

Naoki Yamashita,Tetsuya So,Takeaki Miyata,Takashi Yoshimatsu,Ryuji Nakano,Tsunehiro Oyama,Wataru Matsunaga,Akinobu Gotoh
DOI: https://doi.org/10.21203/rs.3.rs-948192/v1
2021-10-08
Abstract:Abstract Background Cancer stem cells (CSCs) are major contributors to the malignant transformation of cells because of their capacity for self-renewal. Although several CSC markers have been identified in various tumor types, they are primarily used as cancer-prediction markers and for the isolation of CSC populations. Aldehyde dehydrogenase1A1 (ALDH1A1) and CD133 are promising candidate of CSC markers in non-small cell lung cancer (NSCLC). Furthermore, TP53 is frequently mutated in lung cancer, and the loss of its function is associated with malignant characteristics. However, the relationship between CSCs and mutant p53 in lung adenocarcinoma is not well-established. We examined the expression of ALDH1A1, CD133, and mutant p53 in lung adenocarcinoma patients and conducted a clinicopathological study. Methods The subjects of the study were 194 patients who underwent surgery for lung adenocarcinoma. ALDH1A1, CD133, and mutant p53 were immunohistochemically stained in resected specimens from these patients. Results Triple-negative cases without ALDH1A1, CD133, and mutant p53 expression in lung adenocarcinoma were shown to have a much better prognosis than others. Conclusions Our present results suggest that detection of CSC markers and mutant p53 by immunohistochemical staining may be effective in therapeutic strategies for lung adenocarcinoma.
What problem does this paper attempt to address?